Squarepoint Ops LLC Intellia Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

$62.8 Billion
Q3 2024

A detailed history of Squarepoint Ops LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 63,884 shares of NTLA stock, worth $892,459. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,884

Previous 13,280 381.05%

Holding current value

$892,459

Previous $297,000 341.75%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $997,910 - $1.38 Million	50,604 Added 381.05%	63,884 $1.31 Million
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $4.65 Million - $6.33 Million	-232,496 Reduced 94.6%	13,280 $297,000
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $5.62 Million - $7.73 Million	235,739 Added 2348.7%	245,776 $6.76 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $109,384 - $152,741	4,723 Added 88.88%	10,037 $306,000
Q2 2023 Aug 14, 2023	SELL	$34.58 - $46.03 $9.3 Million - $12.4 Million	-268,890 Reduced 98.06%	5,314 $216,000
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $6.1 Million - $8.21 Million	183,080 Added 200.91%	274,204 $10.2 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $2.82 Million - $5.32 Million	84,834 Added 1348.71%	91,124 $3.18 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $339,156 - $450,993	6,290 New	6,290 $352,000
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $2.16 Million - $4.27 Million	-56,057 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $3.27 Million - $6.67 Million	56,057 New	56,057 $4.07 Million
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $9.86 Million - $13.5 Million	-97,871 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $11.9 Million - $16 Million	90,240 Added 1182.54%	97,871 $13.1 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $464,575 - $1.24 Million	7,631 New	7,631 $1.24 Million
Q1 2021 May 17, 2021	SELL	$46.59 - $83.68 $2.09 Million - $3.76 Million	-44,899 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $533,322 - $1.8 Million	-28,323 Reduced 38.68%	44,899 $2.44 Million
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $338,044 - $482,395	19,350 Added 35.92%	73,222 $1.46 Million
Q2 2020 Aug 14, 2020	BUY	$11.14 - $22.87 $600,134 - $1.23 Million	53,872 New	53,872 $1.13 Million
Q2 2019 Aug 14, 2019	SELL	$13.88 - $18.41 $945,922 - $1.25 Million	-68,150 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $93,993 - $129,489	-7,349 Reduced 9.73%	68,150 $1.16 Million
Q4 2018 Feb 14, 2019	BUY	$11.39 - $27.13 $489,758 - $1.17 Million	42,999 Added 132.3%	75,499 $1.03 Million
Q3 2018 Nov 14, 2018	BUY	$25.78 - $32.6 $146,198 - $184,874	5,671 Added 21.14%	32,500 $930,000
Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $331,751 - $510,221	-16,571 Reduced 38.18%	26,829 $734,000
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $212,117 - $381,549	10,917 Added 33.61%	43,400 $915,000
Q4 2017 Feb 14, 2018	BUY	$17.39 - $31.12 $564,879 - $1.01 Million	32,483	32,483 $624,000

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.06B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account

Squarepoint Ops LLC Intellia Therapeutics, Inc. Transaction History